PL2254869T3 - Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 - Google Patents

Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40

Info

Publication number: PL2254869T3
Authority: PL; Poland
Prior art keywords: cx3cr1; neue; und; benzyl; expression
Prior art date: 2008-03-07

Application number

PL09717638T

Other languages

English (en)

Inventor

Angelo Guglielmotti

Guido Furlotti

Giorgina Mangano

Nicola Cazzolla

Barbara Garofalo

Original Assignee

Acraf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-07

Filing date

2009-03-05

Publication date

2017-10-31

2009-03-05 Application filed by Acraf filed Critical Acraf

2017-10-31 Publication of PL2254869T3 publication Critical patent/PL2254869T3/pl

Links

AKQDXNFPEFHRLS-UHFFFAOYSA-N (1-benzylindazol-3-yl)methanol Chemical class C12=CC=CC=C2C(CO)=NN1CC1=CC=CC=C1 AKQDXNFPEFHRLS-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Obesity (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)

PL09717638T 2008-03-07 2009-03-05 Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 PL2254869T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08425139		2008-03-07
PCT/EP2009/052585 WO2009109613A2 (en)	2008-03-07	2009-03-05	Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EP09717638.2A EP2254869B1 (en)	2008-03-07	2009-03-05	Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40

Publications (1)

Publication Number	Publication Date
PL2254869T3 true PL2254869T3 (pl)	2017-10-31

Family

ID=39671487

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL09718467T PL2254870T3 (pl)	2008-03-07	2009-03-05	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
PL09717638T PL2254869T3 (pl)	2008-03-07	2009-03-05	Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL09718467T PL2254870T3 (pl)	2008-03-07	2009-03-05	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1

Country Status (25)

Country	Link
US (3)	US7919518B2 (pl)
EP (3)	EP3181551A1 (pl)
JP (2)	JP5509101B2 (pl)
KR (2)	KR101581828B1 (pl)
CN (2)	CN101945855B (pl)
AR (2)	AR070811A1 (pl)
AU (2)	AU2009221089B2 (pl)
BR (2)	BRPI0907977A2 (pl)
CA (2)	CA2712403C (pl)
CY (2)	CY1117584T1 (pl)
DK (2)	DK2254869T3 (pl)
EA (2)	EA019711B1 (pl)
ES (2)	ES2569330T3 (pl)
GE (2)	GEP20135912B (pl)
HR (2)	HRP20160462T1 (pl)
HU (1)	HUE027098T2 (pl)
IL (3)	IL206893A0 (pl)
LT (1)	LT2254869T (pl)
MX (2)	MX2010009623A (pl)
PL (2)	PL2254870T3 (pl)
PT (1)	PT2254869T (pl)
SG (1)	SG188177A1 (pl)
SI (2)	SI2254869T1 (pl)
UA (2)	UA103605C2 (pl)
WO (2)	WO2009109618A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2262778B8 (en)	2008-03-07	2020-01-01	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
KR101581829B1 (ko)	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도
KR101581828B1 (ko) *	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
SG176885A1 (en) *	2009-08-03	2012-01-30	Acraf	Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates
UA108742C2 (uk) *	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en)	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
EP3338776A1 (en) *	2012-05-01	2018-06-27	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
US9346757B2 (en)	2012-05-18	2016-05-24	Sanofi	Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
JP6257596B2 (ja) *	2012-05-18	2018-01-10	サノフイ	ピラゾール誘導体およびｌｐａｒ５アンタゴニストとしてのその使用
AR093422A1 (es)	2012-11-09	2015-06-03	Colgate Palmolive Co	Copolimeros de bloque para proteccion del esmalte dental
WO2015173786A1 (en) *	2014-05-15	2015-11-19	Boyd Shelley Romayne	Compositions and methods for treating and diagnosing ocular disorders
AU2016277126A1 (en) *	2015-06-12	2017-12-14	Vettore, LLC	MCT4 inhibitors for treating disease
EP3310353A4 (en) *	2015-06-16	2019-02-06	Translatum Medicus, Inc.	COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
CN110114351B (zh)	2016-12-12	2022-09-20	维托尔股份有限公司	Mct4的杂环抑制剂
GB201811169D0 (en)	2018-07-06	2018-08-29	Kancera Ab	New compounds
WO2020026570A1 (ja) *	2018-07-31	2020-02-06	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) *	2018-07-31	2020-02-06	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
EP3990433B1 (en) *	2019-06-25	2026-05-20	Translatum Medicus Inc	PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
FR3101358A1 (fr) *	2019-09-27	2021-04-02	Bioaster	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
CN113929627A (zh) *	2021-10-19	2022-01-14	吕梁学院	一种宾达利的合成方法
WO2024108386A1 (zh) *	2022-11-22	2024-05-30	中国科学院深圳先进技术研究院	抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) *	2023-02-10	2024-08-15	Translatum Medicus Inc.	Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US364371A (en) *		1887-06-07		peice
US416359A (en) *		1889-12-03		Sash-fastener
IT1230441B (it) *	1989-02-07	1991-10-23	Acraf	Eteri della serie dell'indazolo
IT1253703B (it) *	1991-04-22	1995-08-23	Angelini Francesco Ist Ricerca	Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it)	1997-07-28	1999-03-10	Angelini Ricerche Spa	Farmaco attivo nel ridurre la produzione di proteina mcp-1
JP2003502424A (ja)	1999-06-17	2003-01-21	シオノギバイオリサーチコーポレイション	Ｉｌ−１２産生の阻害物質
EP1188438A1 (en)	2000-09-15	2002-03-20	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en)	2000-09-15	2002-04-24	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1369119B1 (en)	2001-03-15	2008-12-17	Seikagaku Corporation	Il-12 expression controlling agents
JP2005519034A (ja)	2001-11-30	2005-06-30	シンタファーマシューティカルズコーポレーション	ピリミジン化合物
WO2005033115A1 (en)	2003-10-07	2005-04-14	Astrazeneca Ab	New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
ES2641815T3 (es) *	2004-10-29	2017-11-14	Eisai R&D Management Co., Ltd.	Tratamiento para enfermedades inflamatorias
TW200628159A (en)	2004-11-10	2006-08-16	Synta Pharmaceuticals Corp	IL-12 modulatory compounds
WO2006060194A1 (en)	2004-11-19	2006-06-08	Synta Pharmaceuticals Corp.	Pyrimidine compounds and uses thereof
UA90707C2 (en)	2005-04-06	2010-05-25	Астразенека Аб	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es)	2005-04-06	2007-05-02	Astrazeneca Ab	Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
EP2262778B8 (en) *	2008-03-07	2020-01-01	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
KR101581828B1 (ko) *	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
KR101581829B1 (ko) *	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도

2009
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active Expired - Fee Related
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active Expired - Fee Related
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en not_active Ceased
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en not_active Ceased
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
2016
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
2017
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown

Also Published As

Publication number	Publication date
MX2010009623A (es)	2010-09-28
KR101599867B1 (ko)	2016-03-04
PT2254869T (pt)	2017-07-18
HUE027098T2 (en)	2016-08-29
CA2712703C (en)	2016-10-11
WO2009109613A2 (en)	2009-09-11
SG188177A1 (en)	2013-03-28
CN101945855B (zh)	2014-12-17
CY1117584T1 (el)	2017-04-26
IL215579A (en)	2015-06-30
EA201071038A1 (ru)	2011-02-28
JP5509099B2 (ja)	2014-06-04
IL207131A0 (en)	2010-12-30
KR101581828B1 (ko)	2015-12-31
MX2010009626A (es)	2010-12-20
EP2254870B1 (en)	2016-02-24
CY1119252T1 (el)	2018-02-14
EA019711B1 (ru)	2014-05-30
EP2254869A2 (en)	2010-12-01
AU2009221089B2 (en)	2013-12-05
AR070810A1 (es)	2010-05-05
US20100311744A1 (en)	2010-12-09
SI2254869T1 (sl)	2017-10-30
AU2009221083A1 (en)	2009-09-11
IL207131A (en)	2013-02-28
EP2254870A2 (en)	2010-12-01
DK2254869T3 (en)	2017-09-04
US20110160205A1 (en)	2011-06-30
UA103605C2 (en)	2013-11-11
UA105170C2 (en)	2014-04-25
CA2712403C (en)	2017-06-06
CN101945855A (zh)	2011-01-12
EP2254869B1 (en)	2017-05-31
BRPI0907977A2 (pt)	2015-08-04
CA2712703A1 (en)	2009-09-11
CN101952256A (zh)	2011-01-19
CN101952256B (zh)	2016-03-16
US8835481B2 (en)	2014-09-16
EA018241B1 (ru)	2013-06-28
ES2637009T3 (es)	2017-10-10
EA201071040A1 (ru)	2011-02-28
EP3181551A1 (en)	2017-06-21
KR20100131432A (ko)	2010-12-15
US20110003874A1 (en)	2011-01-06
DK2254870T3 (en)	2016-05-17
AU2009221083B2 (en)	2013-11-28
GEP20135912B (en)	2013-08-26
GEP20135983B (en)	2013-12-10
KR20100133957A (ko)	2010-12-22
LT2254869T (lt)	2017-08-10
IL206893A0 (en)	2010-12-30
IL215579A0 (en)	2011-11-30
US8283348B2 (en)	2012-10-09
WO2009109613A3 (en)	2009-12-10
ES2569330T3 (es)	2016-05-10
JP5509101B2 (ja)	2014-06-04
HRP20171208T1 (hr)	2017-10-06
HRP20160462T1 (hr)	2016-06-03
WO2009109618A2 (en)	2009-09-11
PL2254870T3 (pl)	2016-07-29
AR070811A1 (es)	2010-05-05
BRPI0907976A2 (pt)	2015-08-04
JP2011513365A (ja)	2011-04-28
US7919518B2 (en)	2011-04-05
JP2011513367A (ja)	2011-04-28
SI2254870T1 (sl)	2016-05-31
CA2712403A1 (en)	2009-09-11
WO2009109618A3 (en)	2009-12-10
AU2009221089A1 (en)	2009-09-11

Publication	Publication Date	Title
SI2254869T1 (sl)	2017-10-30	Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40
PL2170848T3 (pl)	2015-02-27	Pochodne pirazynonu i ich zastosowanie w leczeniu chorób płuc
IL207277A (en)	2015-03-31	New Annotations of 1 - Benzyl - 3 - Hydroxymethylindazole
ZA201000075B (en)	2010-09-29	Purin derivatives for use in the treatment of fab-related diseases
NO20081842L (no)	2008-07-08	Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
AP2965A (en)	2014-09-30	Therapeutic compositions and the use thereof
EP2219448A4 (en)	2011-10-12	THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
AP2490A (en)	2012-10-04	Therapeutic compositions and the use thereof
PL2262777T3 (pl)	2016-08-31	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
PT2390255T (pt)	2016-10-24	Novos aminoglicosídeos e utilizações destes no tratamento de distúrbios genéticos
SI2148667T1 (sl)	2013-12-31	Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
PL2012805T3 (pl)	2014-01-31	Kompozycja lecznicza i jej zastosowanie
ZA201001207B (en)	2010-10-27	Therapeutic formulations for the treatment of cold and flu-like symptoms
ZA201108106B (en)	2013-07-31	Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en)	2010-05-31	Drug combination and its use in the treatment of muscle loss
IL193943A0 (en)	2009-08-03	The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
ZA200904755B (en)	2010-09-29	Use of epothilones in the treatment of osteoporosis and related diseases
IL193944A0 (en)	2009-08-03	The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
PL2224934T3 (pl)	2012-12-31	Zastosowanie osteoblastów w leczeniu zapalnych chorób reumatycznych
HK1145323A (en)	2011-04-15	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
ZA200909073B (en)	2010-09-29	Pyrazinone derivatives and their use in the treatment of lung diseases
IL194275A0 (en)	2009-09-22	Use of digitalis-like compounds in the treatment of affective disorders
IL202502A0 (en)	2011-08-01	Agents for the treatment of inflammatory diseases and methods of using same